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Kaposi's sarcoma-associated herpesvirus (KSHV) is a member of the Gammaherpesvirinae and is causally associated with Kaposi's sarcoma,
primary effusion lymphoma, and multicentric Castleman's disease. The KSHV genome encodes over 85 genes; the function of some is entirely
unknown. We have characterized the transcriptional regulation of a conserved and uncharacterized Gammaherpesvirinae open reading frame,
orf35, which lies in a cluster of several overlapping genes, orf34 to orf38. We identified the transcription start site and analyzed upstream
sequences. We found that expression of the KSHV lytic replication and transcription activator (RTA) strongly increased the orf35 promoter
activity through a 46-nucleotide region which includes a conserved AP-1 binding site. Electrophoretic mobility shift assay demonstrated direct
binding of cJUN and cFOS to the predicted AP-1 binding site. Finally, using a mutated promoter lacking the AP-1 site and dominant-negative
cFOS, we established that the RTA-mediated orf35 transactivation is AP-1-dependent.
© 2007 Elsevier Inc. All rights reserved.Keywords: KSHV, Kaposi's sarcoma-associated herpesvirus; HHV-8, human herpesvirus 8; ORF35, open reading frame 35; RTA, replication and transcription
activator; AP-1, activator protein 1Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV), also
referred to as human herpesvirus-8 (HHV-8), is a gamma-2
herpesvirus which is implicated in the etiology of Kaposi's
sarcoma (KS), primary effusion lymphoma (PEL; also known as
body cavity-based lymphoma (BCBL)), and a subset of
multicentric Castleman's disease (Cohen et al., 2005; Schulz,
2006; Hengge et al., 2002; Dourmishev et al., 2003). KSHV is
closely related to herpesvirus saimiri (HVS), an oncogenic virus
that naturally infects the squirrel monkey, and to a greater
degree to non-human primate gammaherpesviruses (Russo et
al., 1996; Whitby et al., 2003). Among human viruses, KSHV
displays the highest resemblance to the Epstein-Barr virus
(EBV), a tumorigenic lymphotropic gamma-1 herpesvirus
known to be associated with lymphomas and nasopharyngeal
carcinoma. The KSHV genome is encoded on a linear double-⁎ Corresponding author. Fax: +972 3 7384058.
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doi:10.1016/j.virol.2007.08.023stranded DNA, of approximately 165-kbp, which contains over
85 open reading frames (ORFs) (Russo et al., 1996) and an array
of 12 microRNAs (Pfeffer et al., 2005; Cai et al., 2005; Samols
et al., 2005; Pearce et al., 2005; Grundhoff et al., 2006). The
genomic nomenclature of KSHV genes, which has been adapted
for most gammaherpesviruses, is based on the homology to the
HVS ORFs that are consecutively designated according to their
location on the genome from left to right. Divergent KSHV
genes are designated with the prefix K according to their
position within the viral genome. Like all herpesviruses, KSHV
encodes both enzymes involved in nucleic acid metabolism and
DNA synthesis, and structural proteins encompassing the viral
particle. A large number of KSHV-encoded proteins share
sequence and functional similarities with host proteins, and
were presumably captured from the host by molecular piracy.
To date, the functions of several KSHV genes remain unknown,
even among homologues of KSHV.
In common with all other herpesviruses, KSHVexhibits two
divergent phases of infection: lytic (productive) and latent (non-
productive), characterized by distinct gene expression programs
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experimentally by a number of physiologic, biological, or
chemical stimuli, among which, the phorbol ester, 12-O-
tetradecanoyl 13-acetate (TPA), is the most broad, efficient,
and useful inducer (Moore et al., 1996; Renne et al., 1996;
Miller et al., 1997; Davis et al., 2001). All lytic stimuli induce
expression of the replication and transcription activator (RTA)
encoded by orf50 (Lukac et al., 1998; West and Wood, 2003;
Deng et al., 2007). In turn, RTA activates a cascade of viral lytic
program, resulting in the ordered expression of viral proteins,
and ultimately leading to the release of progeny viruses and host
cell death. Initiation of the lytic viral cascade by RTA is
mediated through the transcriptional activation of selected viral
promoters, including orfK1, orf6 (single-stranded-DNA-bind-
ing protein), orf9 (DNA polymerase), orfK2 (viral interleukin-6
homolog), orfK5 (modulator of immune regulation, MIR2),
orfK6 (viral MIP-1), polyadenylated nuclear (PAN) RNA (nut-
1), orf50 (RTA), orfK8 (replication-associated protein, RAP),
orf57 (mRNA transport and accumulation protein, MTA),
orfK9 (viral IRF), orf59 (DNA replication protein), orf21
(thymidine kinase), orfK12 (Kaposin), orfK14 (viral OX-2),
and orf74 (viral G protein-coupled receptor) (Bowser et al.,
2006; Chen et al., 2000; Deng et al., 2002; Haque et al., 2000,
2006; Jeong et al., 2001; Lukac et al., 1998; Song et al., 2001,
2003; Wang et al., 2003b). This wide range of promoter
transactivation occurs through the direct binding of RTA to
selective DNA motifs, termed RTA-responsive elements
(RREs) (Liao et al., 2003; Bowser et al., 2006; Chang et al.,
2002), or through the binding to other cellular transcription
factors that tether RTA to the DNA, such as cAMP response
element binding protein (CREB)-binding protein (CBP), Oct-1,
CAAT/enhancer-binding protein alpha (C/EBP-α), RBP-Jκ
(CSL), Sp1, MGC2663, and TATA-binding protein (TBP)
(Bowser et al., 2006; Chang et al., 2005a; Gwack et al., 2001;
Liang and Ganem, 2003; Liang et al., 2002; Sakakibara et al.,
2001; Wang et al., 2001, 2003a, 2003b; Ye et al., 2005; Zhang et
al., 1998). In addition, RTA may manipulate viral and cellular
gene transcription through the modulation of key signaling
proteins, such as cJUN and STAT3 (Yu et al., 2005; Gwack et
al., 2002).
In an effort to increase our understanding of KSHV
pathogenesis, we focused our attention on orf35, a previously
uncharacterized open reading frame located in a lytic cluster of
genes. Since orf35 is included within a limited set of genes that
are transiently expressed prior to the establishment of KSHV
latency and early after infection of endothelial and fibroblastic
cell cultures (Krishnan et al., 2004), we assume that it may
mediate crucial functions during infection. Consistent with this
hypothesis, a high abundance of orf35 transcripts is detected
early after infection with the rhesus monkey rhadinovirus (RRV)
(Dittmer et al., 2005). An additional hint for the importance of
ORF35 comes from a recent study, which employed signature-
tagged transposon mutagenesis to generate murine gammaher-
pesvirus-68 (MHV-68) mutants, and demonstrated that ORF35
is required for in vitro infection (Song et al., 2005).
Understanding the mechanisms by which ORF35 expression
is regulated may shed light on its role in the life cycle of KSHV;we therefore examined its transcriptional kinetics and control.
In the present study, we identified the 5′ and 3′ ends of the
major ORF35 transcript, and characterized its transcription
kinetics in PEL cells upon virus reactivation by TPA. We also
analyzed sequences upstream of the transcription start site for
their ability to activate a luciferase reporter construct. We show
that the KSHV immediate-early protein RTA transactivates the
orf35 promoter element and that this transactivation is AP-1-
dependent.
Results
Sequence analysis of ORF35 encoded by KSHV
Like its homologs from other gammaherpesviruses, the
KSHV orf35 coding sequence partially overlaps its adjacent
genes, namely orf34 and orf36. It is the second-stream of a
cluster of overlapping orf34 to orf38 lytic genes, all oriented in
the same direction (Russo et al., 1996). The KSHV orf35
encodes a protein of 150 amino acids with a calculated
molecular mass of 16.8 kDa and a pI of 5.97. ORF35 protein is
present in all complete genomes of the Gammaherpesvirinae,
and shares high degree of sequence similarity at the amino acid
level. Fig. 1 depicts the alignment of the amino acid sequences
encoded by the ORF35 proteins of KSHV, RRV, HVS, AthV-3,
BHV-4, mHV-68, and EBV, which was performed using the
ClustalW program. Like other KSHV-encoded proteins, KSHV
ORF35 is most similar to the ORF35 encoded by rhesus
rhadinovirus 17577 (RRV17577), with which it shares 60%
similarity and 35% identity. Lower similarity and identity scores
were found between KSHV ORF35 and corresponding
homologs encoded by other Gammaherpesvirinae. The rela-
tively high sequence conservation of ORF35 in these related
viruses suggests that it may exhibit functional conservation
during the course of viral infection.
A recent PSI-BLAST search revealed similarity between
Gammaherpesvirinae ORF35 and the ORF48 protein of the
alphaherpesvirus, equine herpesvirus 4, and further PSI-
BLAST iterations identified similar homology in all members
of this subfamily (Mills et al., 2003). The ORF48 protein
belongs to the UL14 family of viral proteins, which are present
as a minor component of the virion tegument and possess
multiple functions, including molecular chaperone activity
(Cunningham et al., 2000; Yamauchi et al., 2001, 2003).
Nevertheless, we found that unlike UL14, the ORF35 protein
encoded by KSHV, lacks homology with the substrate-binding
domain included in the heat-shock protein (HSP) 70 family of
proteins.
No mammalian homologues of ORF35 proteins have been
identified. The KSHVORF35 protein sequence does not include
a signal peptide to target the protein to a specific subcellular
compartment, nor a nuclear localization signal. Comparison of
the KSHV ORF35 protein sequence with the Eukaryotic Linear
Motif (ELM) database identified several potential phosphoryla-
tion sites. Three putative sumoylation sites (ψKXE, where ψ is a
hydrophobic amino acid) were found using a Sumoylation site
prediction tool. Of note, several gammaherpesviruses contain at
Fig. 1. Alignment of the amino acid sequence of KSHV ORF35. (A) ClustalW alignment of the amino acid sequences of seven ORF35 homologs encoded by KSHV,
RRV (Rhesus rhadinovirus), HVS (Herpesvirus saimiri), mHV-68 (Murine herpesvirus 68), BHV-4 (Bovine herpesvirus 4), AthV-3 (Ateline herpesvirus 3), and EBV
(Epstein-Barr virus). Identical amino acids are indicated by stars, conserved substitutions are indicated by semicolons, and semi-conserved substitutions are indicated
by single dots. Putative sumoylation sites are indicated by gray shading. (B) Percent amino acid similarity and identity of KSHV ORF35 to corresponding
gammaherpesvirus ORF35 proteins, calculated using BLOSUM62 amino acid substitution matrix.
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region, yet their functional significance remains to be elucidated
(Fig. 1A).
Transcription of orf35 in PEL cells
To determine the kinetics of the synthesis of the KSHV-
encoded orf35 mRNA in PEL cells, we induced a lytic
transcription program in the KSHV-infected BCP-1 cells with
TPA, and employed RT-PCR to detect transcripts at 24, 48, and
72 h post induction. As shown in Fig. 2A, low expression of
orf35 transcript was observed in BCP-1 cells growing under
standard growth conditions. Increased transcription of orf35
was evident after 24 h of TPA treatment, peaking at 48 h and
decreasing at 72 h. A minor inhibition of orf35 transcription
was evident in cells treated with a combination of TPA and the
viral DNA polymerase inhibitor PAA for 48 h, suggesting that
the orf35 transcript is not a late gene. Northern blot hybri-
dization of total cellular RNA to detect the orf35 transcript
confirmed these results and allowed determination of the
transcript size. Induction of a predominant 3.4 kb transcript wasobserved after TPA stimulation, peaking at 48 h after sti-
mulation (Fig. 2B). A similar transcript size was previously
described in lytic BC-3, JSC-1, and BCBL-1 cell lines (Haque
et al., 2006; Cannon et al., 1999).
Identification of the intact orf35 cDNA
To further characterize and map the full-length orf35
transcript, we screened a BC-1 cDNA library with a
radiolabeled orf35 PCR probe. The longest cDNA clone (ϕ5)
of 3327 bp, included orf35 to orf38, was assumed to represent
an authentic full-length cDNA. Nucleotide sequence analysis of
this cDNA clone gave no indication of splicing. A highly
conserved hexanucleotide signal, AAUAAA, at positions
58,853 to 58,858 within the coding region of orf38, was
identified; this sequence could potentially serve as a polyA
signal for cleavage to generate the 3′ transcript end for
polyadenylation. Using computer analysis of orf35 and down-
stream sequences, we identified two additional potential polyA
signals within orf37 (positions 58,004 AAUAAA and 58,341
AUUAAA) and one within orf38 (position 58,834 AUUAAA),
Fig. 2. Semi-quantitative RT-PCR and Northern blot hybridization demonstrating orf35 transcription in PEL cells. (A) Total RNAwas prepared from BCP-1 cells prior
to and following induction with TPA for the indicated time periods, and from cells that were treated with TPA and PAA for 48 h. RNAwas reverse transcribed using
random primers and subjected to PCR using orf35, and GAPDH primers. PCR with primers that target the orf65 late gene was used to control for the inhibitory activity
of PAA. −RT reactions were used to control for DNA contamination. High molecular weight DNA from BCP-1 cells was used as a positive control for PCR, and
reaction mixture (RM) with no template controlled for DNA contamination. (B) Northern blot of total cellular RNA from BCBL-1 cells prior to and following
induction with TPA, probed with a 32P-labeled DNA orf35 probe. GAPDH was used as a control for RNA loading.
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genomic region. However, our findings together with previous
reports (Haque et al., 2006) suggest that the major polyA signal
used in PEL cells upon TPA stimulation is located at position
58853.
To accurately determine the transcription start site, we
designed a primer (PE) that would anneal to a site located 51
bases 3′ to the orf35 ATG and performed primer extension.
Total RNA was isolated from non-induced and TPA-induced
BC-1, BCBL-1 and BCP-1 cells 48 h after induction of lytic
replication. PE synthesized four oligonucleotide products that
were predominantly observed after TPA treatment (Fig. 3A);
three extended several nucleotides upstream from the start site
of the largest cDNA clone. Taken together, as depicted in Fig.
3B, our mapping of the intact KSHV orf35 transcript revealed
that it encompasses 3315–3367 nt and starts at positions
55,566–55,514, which are 73–125 nt upstream of orf35 AUG
and within the orf34 coding region. The transcript is not spliced
and contains the coding sequences of orf35 to orf38. Similar
findings have recently been reported by Haque et al. (2006);
however, their transcript mapping indicates a single start site at
position 55567. In addition, this group identified a second lowabundance transcript that contains the orf34 to orf38 cluster of
genes (Haque et al., 2006).
Expression of ORF35 protein
We cloned PCR products of orf35 in-frame with an N-
terminal HA or GFP tags into plasmids that allow gene
expression in mammalian cells. In addition, we obtained rabbit
antibodies to an ORF35 peptide (amino acids 3–17: STNSKRE-
FIKSALEA). Using these reagents, we determined the
apparent molecular weight of ORF35 on SDS-PAGE as
∼17 kDa. In line, a 43-kDa protein was detected on immu-
noblot prepared from GFP-ORF35 transfected cell extracts
(Fig. 4A). This protein size is compatible with the calculated
molecular weight of ORF35, and was also detected by our
ORF35 polyclonal antibody (Fig. 4A). We next examined the
intracellular localization of the ORF35 protein by GFP fluo-
rescence on cells transfected with GFP-ORF35 fusion protein
expression plasmid. As shown in Fig. 4B, unlike GFP, GFP-
ORF35 is predominantly cytoplasmic. Similar results were
obtained on cells transfected with HA-ORF35 expression
plasmid and anti-HA antibody (data not shown). Taken
Fig. 3. Initiation site of the KSHV orf35 transcript identified by primer extension and depiction of the transcript. (A) Total cellular RNA was prepared from BC-1,
BCP-1 and BCBL-1 cells prior to (−) and 48 h after stimulation by TPA (+). Primer PE was end-labeled with [γ-32P]ATP, hybridized to 10 μg of RNA at 60 °C, and
extended at 42 °C. Reaction products were precipitated with ethanol and resolved on 6% polyacrylamide, 7 M urea gel in Tris–borate–EDTA. Sequencing ladder
indicates the size of the primer extension product. The arrowheads in the right indicate the position of the cDNA products, and the numbers indicate their nucleotide
position. (B) Map of genes in orf35 region is shown with nucleotide positions as designated by Russo et al. (1996). The illustration is based on data obtained by
screening of a cDNA library (ϕ5) and primer extension (vertical black arrows).
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its predicted molecular weight with no apparent post-
transcriptional modifications.
To determine if the cDNA phage clone (ϕ5), which was
shown to contain the cluster of orf35 to orf38 genes, encodes
ORF35 protein, we performed in vitro transcription/translation
using a plasmid containing full-length HA-tagged ORF35 as the
positive control. The results (Fig. 4C) showed two translation
products of 19 and 17-kDa for pcDNA/HA-ORF35, suggesting
that this plasmid can produce both HA-tagged ORF35 and
ORF35 alone using the AUG translation initiation codons from
the HA or from ORF35, respectively. A similar translation
product of 17-kDa was evident from the phage clone, indicatingits potential to produce ORF35. In addition, we observed a high
abundance translation product of approximately 50-kDa. The
expected molecular weights of ORF36, ORF37, and ORF38
proteins are 50.3-, 55.1-, and 6.8-kDa, respectively. Hence, the
products of the coupled in vitro transcription and translation
reaction suggest that the transcript encoded in phage clone ϕ5
can potentially serve as a template for the translation of ORF35
as well as proteins beyond ORF35.
Basal activity of orf35 promoter
The 533-nt upstream sequence from the orf35 translation
start site was scanned with Genomatix MatInspector program to
Fig. 4. Expression of ORF35 protein. HEK-293T cells were transfected with the indicated plasmids and cell extracts were analyzed by Western blot with anti-HA
antibody and sequentially with anti-GFP antibody. Expression of 17-kDa and 43-kDa recombinant ORF35 proteins is clearly seen. The same bands were evident when
a second Western blot was carried with antibodies to ORF35 peptide (A). Cells were transfected with pEGFP-C1 or pGFP-ORF35 and then fixed at 24 h post
transfection. The fluorescence of GFP and GFP-ORF35 fusion protein was visualized in propidium iodide (PI) stained cells with a confocal laser microscope. As
shown, ORF35 is predominantly cytoplasmic (B). The excised clone from phage screening was in vitro transcribed/translated, along with a plasmid containing HA-
ORF35 as a positive control for ORF35. The resulting band of 17-kDa was identical in the T3/T7 polymerase translated ϕ5 clone and ORF35 control plasmid.
Additional protein products were also produced (C).
19S.-R. Masa et al. / Virology 371 (2008) 14–31identify potential transcription factor binding sites (Cartharius et
al., 2005). Several conserved transcription factor recognition
sites, including C/EBP, GATA-1, Sp-1, AP-1, and RBP-Jκ, were
identified, whereas no conserved RTA-responsive elements
(RREs) was found (Fig. 5). Potential hypoxia regulated
elements have been recently identified upstream to this regionand confirmed to mediate hypoxia response (Haque et al.,
2006).
To identify the cis-acting elements necessary to activate
orf35 transcription, a series of 5′ truncated deletion constructs
was synthesized. Fragments containing sequences starting
adjacent to the orf35 transcription initiation site (genomic
Fig. 5. Nucleotide sequence of the KSHV orf35 promoter region. The sequence was taken from GeneBank KSU75698, nt 55105 to 55641, and corresponds to the
region between −533 and +1 (ATG) relative to orf35. Potential transcription start sites that were identified by primer extension are boldface and indicated by gray
shading while the 5′-end of ϕ5 is also underlined. Consensus motifs representing putative transcription factor binding sites that were identified with MatInspector
program are depicted. Locations of truncated orf35 promoter fragments used in luciferase reporter assays are indicated by arrows according to their position and
designation. The AP-1 binding site which is included in the −262 promoter fragment (−262ORF35p) is marked by gray shading.
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were generated by PCR and cloned upstream to a luciferase
reporter gene in the pGL3-Basic vector. The nomenclature for
each plasmid (−533ORF35p, −362ORF35p, −262ORF35p,
−216ORF35p, and −176ORF35p) was defined according to the
distance from the ATG, and their positions are indicated in Fig.
5. These constructs were transiently transfected into HEK-293T
cells which were previously shown to support KSHV infection
in vitro (Krishnan et al., 2005). Transfections were performed in
triplicate, repeated three times, and normalized against β-
galactosidase reporter activity, which was used to control for
transfection efficiency. Promoter activity, which was measured
by luciferase units for each of the constructs, is presented as fold
activation over pGL3-Basic control vector. With the exception
of the −176ORF35p and −216ORF35p promoter constructs,
the three other promoter constructs (− 262ORF35p,
−362ORF35p, and −533ORF35p) produced a significant
transcriptional activity over the pGL3-Basic vector (Fig. 6A),
indicating that sequences as close as 262 nucleotides upstream
of the orf35 transcription start site contain promoter activity.
This finding also indicates that the orf35 promoter may be
active in HEK-293T cells in the complete absence of any KSHV
gene product, though repression of this element in KSHV-
infected cells is not excluded.
RTA activates the orf35 promoter in a reporter system
The early transcription pattern of orf35 suggested that it
might be activated by the KSHV-encoded protein RTA. To verify
that the orf35 promoter is a target for RTA, we examined the
effect of RTA on the transcriptional activity of orf35 promoter
fragments. RTAwas expressed from a pcDNA3-ORF50 vector,
and the fold activation over pGL3-Basic for each promoterfragment was compared to that of a pcDNA3 control vector (Fig.
6B). All five reporters investigated were significantly stimulated
by RTA. RTA could activate the −533ORF35p promoter
fragment about ∼170-fold as compared to an empty vector.
Likewise, RTA increased the activation of the −262ORF35p
promoter construct ∼200-fold over cotransfection with
pcDNA3 vector. However, for the −216ORF35p promoter
construct, transactivation by RTA was only 18-fold over
cotransfection with pcDNA3, suggesting that the 46-bp region
included in the −262ORF35p construct, and absent in the
−216ORF35p reporter construct, contains DNA elements that
mediate a potent RTA response. Collectively, these reporter
assays demonstrated that RTA can greatly activate the orf35
promoter in HEK-293T cells, and suggest that a predominant
RTA-responsive region resides in the 46-nt region which is
included in the −262ORF35p reporter plasmid.
RBP-Jκ is dispensable for the activation of orf35 promoter by
RTA
As indicated above and shown in Fig. 5, we identified two
RBP-Jκ binding sites in the sequence upstream to the
transcription initiation site of orf35. Both are included in
−262ORF35p reporter construct whereas the more conserved
one (TTCCCAC) is included also in the −216ORF35p
reporter construct. Previous studies have shown that RTA
can activate several KSHV lytic promoters through regulation
of the activities involving the RBP-Jκ binding sites (Liang
and Ganem, 2003; Liang et al., 2002; Chang et al., 2005b,
Lan et al., 2005; Carroll et al., 2006). We therefore wanted to
determine if RTA regulates orf35 promoter through RBP-Jκ.
Notably, as shown in Fig. 6B, the −216ORF35p reporter
construct which contains the fully conserved RBP-Jκ binding
Fig. 6. ORF35 promoter activity in HEK-293T cells. (A) Basal activity of the orf35 promoter deletion constructs in HEK-293T cells that were transfected with 0.5 μg
of each of the orf35 promoter constructs. (B) For RTA activation assay, 0.5 μg of each of the orf35 promoter constructs and 0.25 μg of a β-galactosidase expression
plasmid were transfected with either 1 μg of pcDNA3-RTA expression plasmid or pcDNA3 vector into the HEK-293T cell line. Cells were harvested 48 h post
transfection and assayed for relative luciferase activity (RLU). Relative activation was calculated as normalized luciferase activity (Luciferase activity/β-galactosidase
activity) divided by the normalized activity in cells transfected with the pGL3-Basic reporter construct alone. Error bars represent the standard deviation of triplicate
samples. The results shown are representative of those from three similar experiments.
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this site is dispensable for the activation by RTA. Yet, we
hypothesized that it might be functional within the context of
a larger promoter fragment, and therefore set to investigate
the activity of −216ORF35p and −262ORF35p reporter
constructs in mouse fibroblast cells that lack RBP-Jκ (OT11),
a defect that can be reversed by the expression of RBP-Jκ.
We selected this experimental system because it has been
widely used to demonstrate the role of RBP-Jκ in promoter
activation by RTA (Liang and Ganem, 2003, 2004; Liang et
al., 2002; Chang et al., 2005b; Lan et al., 2005). Furthermore,
PAN1 promoter, previously shown to be regulated by RBP-Jκ
was used as a positive control in our experiments. As shown
in Fig. 7, activation of PAN1 promoter was evident in OT11
cells upon RTA expression, and this activation was further
augmented upon expression of RBP-Jκ. This is in line with
previous findings (Liang et al., 2002). Similarly, the orf35
promoter by RTA activity increased upon RTA expression,
but the expression of RBP-Jκ did not enhance its activity. Onthe contrary, the expression of RBP-Jκ abolished the
activation of orf35 promoter by RTA. This finding, together
with the relatively small transcriptional activation of
−216ORF35p reporter construct in HEK-293T cells led us
to conclude that the foremost activation of orf35 promoter by
RTA is not through RBP-Jκ.
The RTA-mediated orf35 transactivation is AP-1-dependent
To identify the predominant RTA response element in orf35
promoter, we then focused on positions 55,376 to 55,422 that
are included in the highly RTA responsive −262ORF35p
reporter construct but absent in the shorter poorly RTA
responsive −216ORF35p reporter construct. We hypothesized
that RTA could activate the −262ORF35p reporter by direct or
indirect modes. Direct activation of −262ORF35p reporter can
take place through direct binding of RTA to response elements
within this fragment; however, known RRE motifs could not be
identified in this sequence.
Fig. 7. Role of RBP-Jκ in the activation of orf35 promoter by RTA. RBP-Jκ−/− OT11 mouse fibroblast cells were cotransfected with 0.5 μg PAN1, −216ORF35p, or
−262ORF35p reporter construct together with 1.5 μg pcDNA-RTA, pSG5/Flag-RBP-Jκ, or with both pcDNA-RTA and pSG5/Flag-RBP-Jκ. The total amount of
effector plasmid DNA used in each transfection was normalized to 3 μg by adding empty pcDNA3 vector DNA. Determination of the luciferase activity and
calculation of the relative activation were performed as described in Fig. 6. The results shown are representative of those from three similar experiments.
22 S.-R. Masa et al. / Virology 371 (2008) 14–31To determine whether RTA activates the −262ORF35p
reporter through direct contact, we performed an electrophoresis
mobility shift assay (EMSA) with a 32P-labeled oligonucleotide
probe (ORF35-PWT) that included the nucleotides between
positions −216 and −262 relative to the orf35 start site. Direct
binding experiments of RTA to this fragment using nuclear
extracts from cells overexpressing RTA or in vitro translated
reticulocyte lysates failed to demonstrate binding of RTA to this
region (data not shown). However, using the MatInspector
computer program, we identified a conserved AP-1 binding site
(5′-TGAGTCA-3′) located between −262ORF35p and
−216ORF35p (Fig. 5). AP-1 complexes are ubiquitous hetero-
dimeric transcription factors composed of cJUN and cFOS
subfamilies. The consensus AP-1 binding element is present in
the promoter regions of several KSHV lytic genes, including the
orf50 (RTA), orfK8 (RAP), and orf57 (MTA) (Byun et al., 2002;
Wang et al., 2004; Gonzalez et al., 2006). Furthermore, it has
been shown that RTA increases cJUN expression and that these
proteins interact to increase RTA transcriptional activation
(Wang et al., 2004; Gwack et al., 2001). Therefore, we
hypothesized that AP-1 family members may participate in
transactivation of the orf35 promoter by RTA protein. To test the
ability of the AP-1 site to bind JUN-FOS complexes, we
performed EMSAwith in vitro-translated HA-tagged cFOS and
untagged cJUN proteins and a 32P-labeled oligonucleotide
ORF35-PWT probe. An AP-1 shift band, which was success-
fully competed by excess unlabeled probe and further super-
shifted by the addition anti-HA antibody, was evident in the
presence of cFOS and cJUN (Fig. 8). No additional shifted bands
were noticed when in vitro translated RTA was added,
suggesting that the AP-1 complex which is formed on the
DNA does not tether RTA to the orf35 promoter at this site.
We further evaluated the effect of AP-1 on the orf35 promoter
by cotransfecting cJUN and cFOS expression plasmids with the
−262ORF35p reporter segment. The combined increase of
transactivation by cotransfected cJUN and cFOS proteins on the−262ORF35p segment reached almost 5-fold at the higher doses
of cJUN and cFOS (Fig. 9A), indicating that the AP-1
transcription factor complex affects the activity of the orf35
promoter. The AP-1 complex is thought to be one of the most
important targets through which TPA stimulates gene expression
(Angel et al., 1987; Hess et al., 2004). When transfected into
HEK-293T cells, the −262ORF35p reporter segment was res-
ponsive to TPA treatment after 24 h, showing 4-fold increased
luciferase activity as compared to non-treated cells (Fig. 9A).
When this promoter segment was cotransfected with cJUN plus
cFOS plasmids and the transfected cells treated with TPA,
promoter activity was stimulated 13-fold at the higher doses of
cJUN and cFOS, indicating that TPA synergistically stimulates
transactivation by AP-1 on the orf35 promoter (Fig. 9A).
Importantly, overexpression of cJUN and cFOS failed to further
augment the activation of orf35 promoter by RTA (Fig. 9B).
Thus, these cotransfection results are consistent with the EMSA
data and demonstrate that cJUN along with cFOS transactivate
the orf35 gene promoter by a mechanism that involves a direct
binding to the AP-1 site at the position −249 to −243 relative to
the orf35 ATG; however, direct AP-1 DNA binding without
RTA appears not to be the dominant determinant of transcrip-
tional activation.
To further determine the effect of the AP-1 transcription
complex on RTA-mediated transactivation of the orf35 promo-
ter, we constructed a reporter plasmid with mutations in the
putative core AP-1 binding sequence within the −262ORF35p
reporter segment (Fig. 10A). Reporter assays were carried in
HEK-293T cells transfected with the wild-type −262ORF35p
reporter segment or with a mutated −262ORF35mp reporter. As
shown in Fig. 10B, the mutant orf35 reporter segment showed a
4-fold decrease in the responsiveness to RTA in an RTA dose-
dependent manner. This suggests that direct DNA binding of
AP-1 is a dominant determinant of RTA-induction.
To further confirm the essential role of AP-1 complex in
RTA-mediated orf35 transactivation, we cotransfected HEK-
Fig. 8. Identification of an AP-1 binding site in the KSHV orf35 promoter by EMSA assay. (A) Sequence of the orf35 promoter wild-type (PWT) probe used in EMSA
experiments. The putative AP-1 site is boxed. (B) Results of an EMSA experiment showing the AP-1-binding ability of the AP-1 motif in the orf35 promoter. Lane 1,
only ORF35-PWT; lane 2, unprogrammed reticulocyte lysate; lane 3, in vitro-cotranslated HA-tagged cFOS and cJUN; lanes 4 and 5, excess unlabeled probe (×10,
×100); lane 6, mouse anti-HA antibody added to generate a specific supershifted band; lane 7, in vitro-cotranslated HA-tagged cFOS and cJUN mixed with in vitro
translated RTA; lane 8, antibody control. Protein samples were incubated with the 32P-labeled ORF35-PWT probe. AP-1 specific shifted bands are marked; SS,
antibody supershift.
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FOS), RTA, and either the wild-type −262ORF35p reporter
segment or the mutated −262ORF35mp reporter segment (Fig.
10C). Comparable levels of RTA expression were confirmed by
Western blot analysis (Fig. 10D). The addition of equivalent
amounts of A-FOS and RTA reduced the RTA-mediated
−262ORF35p transactivation from 129-fold to 72-fold which
is almost half of the fold activation observed, while addition of 2-
equivalent amounts of A-FOS reduced this reporter transactiva-
tion to 33-fold, which is close to the RTA-mediated transactiva-
tion activity of the mutant reporter. Interestingly, the addition of
A-FOS reduced the RTA-mediated −262ORF35mp transactiva-
tion from 36-fold to 20-fold, indicating that the AP-1 trans-
cription complex contributes to orf35 transactivation through
additional sites besides the AP-1 site we investigated. Thus,
these data confirm that the major RTA-mediated orf35
transactivation is AP-1-dependent; nevertheless, there are likely
to be additional weaker target sites.
Discussion
In this study, we identified and characterized the predomi-
nant KSHV orf35 transcript in PEL cells. To identify the intact
full-length orf35 transcript, we performed RT-PCR, Northern
blot hybridization, screening of a cDNA library, and primer
extension assays. We found that orf35 is transcribed as part of a
polycistronic transcript that also contains orf36 to orf38 genes.
This transcript is produced with early kinetics upon virus
reactivation. The orf35 transcript is 3315–3367 bases long,including a 73–125-nucleotide 5′-UTR which is within orf34
coding sequences, and a 7-nucleotide 3′-UTR with a polyA
signal within orf38 coding sequences. Similar results were
recently reported (Haque et al., 2006); nonetheless, we
identified an extended 5′-UTR and demonstrated that orf38 is
also present in the orf35 transcript. An additional transcript
containing orf35, which also includes orf34, has been
previously reported (Haque et al., 2006). However, it appears
that in PEL cells the predominant transcript from this region
contains the orf35-orf38 gene cluster. Of note, upon virus
infection the transcription pattern of orf35 differs from the other
genes in the cluster (Krishnan et al., 2004). Because the closest
potential polyA signal downstream to orf35 is localized to the
orf37 coding sequences, other alternatively spliced orf35
transcripts probably exist during this phase.
The functions of the orf36 and orf37 gene products have
been elucidated. orf36 encodes a serine protein kinase, which is
localized to the nucleus of infected cells, and is capable of
phosphorylating ganciclovir and activating the cJUN N-
terminal kinase signaling pathway (Cannon et al., 1999;
Hamza et al., 2004; Park et al., 2000). ORF37, termed shutoff
and exonuclease (SOX) protein, possesses DNase and host
shutoff activities (Glaunsinger and Ganem, 2004). orf34, orf35,
and orf38 encode proteins with unknown functions. The
necessity of these gene products during various phases of
infection is also unknown. orf34 to orf38 genes partially
overlap each other and their translation route is currently
unclear, though, it probably involves alternatives to the ordinary
scanning mechanism. Furthermore, translation products from
Fig. 9. KSHV orf35 promoter is transcriptionally activated by AP-1. (A) cJUN and cFOS activate the −262ORF35p segment in luciferase reporter assays. HEK-293T
cells were transfected with 0.25 μg of −262ORF35p reporter segment together with the indicated amounts of effector plasmid DNAs encoding cJUN, cFOS, and RTA.
The total amount of effector plasmid DNA used in each transfection was normalized to 2.25 μg by adding empty pcDNA3 vector DNA. TPA was added into the
medium, and the cells were incubated for 24 h before harvesting. (B) Overexpression of cJUN and cFOS fail to further augment RTA activation of orf35 promoter.
Error bars represent the standard deviation of triplicate samples. The results shown are representative of those from three similar experiments.
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phases, according to the translation machinery involved in their
production. Nevertheless, we show that a coupled in vitro
transcription and translation reaction of a cDNA clone containing
the orf35 to orf38 genes produced a predominant band of
approximately 50-kDa, which probably corresponds to either the
orf36 or orf37 gene products. A 17-kDa protein band, which
likelymatches the orf35 gene product was also evident supporting
the potential of this transcript to produce ORF35 protein.
ORF35 protein is highly conserved among all complete
genomes of the Gammaherpesvirinae and shares a limited
sequence similarity with the alphaherpesvirus UL14 gene
product. Unlike UL14, ORF35 has not been detected inKSHV nor in mHV-68 or in EBV virion preparations that
were analyzed by mass spectrometric analysis (Bechtel et al.,
2005; Bortz et al., 2003; Johannsen et al., 2004; Zhu et al.,
2005). However, ORF35 has been detected in purified RRV
particles (O'Connor and Kedes, 2006). UL14 protein has been
suggested to possess multiple functions, including a molecular
chaperone activity. Its expression is mostly cytoplasmic, but it
also accumulates in the nucleus upon induction of cellular stress
conditions (Yamauchi et al., 2002). Likewise, we observed a
predominant cytoplasmic localization of KSHV ORF35. UL14-
deficient mutant exhibits an extended growth cycle and appears
to be compromised in the efficient transit of virus particles
(Cunningham et al., 2000). Significant suppression of apoptosis
Fig. 10. RTA-mediated orf35 transactivation is AP-1-dependent. (A) Schematic diagram of the wild-type and the mutated orf35 promoter region used in transfection
experiments. (B) HEK-293T cells were cotransfected with 0.25 μg target reporter plasmid DNA encoding either wild-type −262ORF35p (solid bars) or the point
mutated version −262ORF35mp (open bars), and 0.5 or 1 μg of effector plasmid DNA encoding RTA. The total amount of effector plasmid DNA used in each
transfection was normalized to 2.25 μg by adding empty pcDNA3 vector DNA. (C) Dominant negative c-FOS (A-FOS) inhibited induction of the RTA-mediated orf35
transactivation. HEK-293T cells were cotransfected with 0.375 μg target reporter plasmid DNA encoding either wild-type −262ORF35p (solid bars) or the point
mutant −262ORF35mp (open bars), 1 μg of RTA expression plasmid, and 1 or 2 μg of A-FOS expression plasmid. The total amount of effector plasmid DNA used in
each transfection was normalized to 3.375 μg by adding empty pcDNA3 vector DNA. (D) Protein extracts were prepared from transfected cells, and equal amounts of
protein (30 μg) were loaded per lane. Following SDS-PAGE and transfer of proteins to nitrocellulose, blots were probed for RTA, Flag (to detect A-FOS) and Tubulin
indicating comparable amounts of RTA in each transfection condition.
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(Yamauchi et al., 2003), and nuclear translocation of two viral
cytoplasmic encapsidation proteins (VP26 and UL33) is
induced in UL14 expressing cells (Yamauchi et al., 2002).
The functional similarity between UL14 and ORF35 proteins
remains to be demonstrated; however, ORF35 may possess
different functions because the domain included in the heat-
shock proteins and UL14 is missing in KSHV ORF35.
In this study, we have documented a strong transcriptional
activation of the orf35 promoter by RTA. This promoter has
been recently shown to contain a functional hypoxia-responsive
element which plays a critical role in its hypoxic transcriptional
activation (Haque et al., 2006). orf35 promoter also contains
conserved binding sites to RBP-Jκ; nonetheless, we have
demonstrated that the activation by RTA is not through the
interaction with this cellular transcription factor as shown for
several other RTA-activated KSHV promoters (Liang and
Ganem, 2003; Liang et al., 2002; Chang et al., 2005b, Lan et
al., 2005; Carroll et al., 2006). We revealed a 46-nucleotide
region which includes a conserved AP-1 binding site and
possesses the predominant responsiveness to RTA. However,
neither the RTA-responsive 46-nucleotide region nor the intact
orf35 promoter appears to share sequence similarity with the
RTA-responsive elements (RREs) found in the PAN, Kaposin,
orfK8, orf57, orfK1, and vIL-6 promoters (Chang et al., 2002,
2005a; Deng et al., 2002; Duan et al., 2001; Lukac et al., 1998,
1999; Song et al., 2002a, 2002b; Bowser et al., 2006). Moreover,
RTA did not bind this 46-nucleotide fragment when tested by
EMSA and added to the DNA probe alone or together with cJUN
and cFOS. On the other hand, given that (i) RTA transcriptional
activation of orf35 promoter has not been further augmented by
cJUN and cFOS overexpression, (ii) mutations in the putative
AP-1 binding sequences markedly reduced the responsiveness
of the orf35 promoter to RTA, and (iii) expression of dominant-
negative cFOS decreased RTA activation of orf35 promoter, our
data establish the requirement of AP-1 binding for RTA
activation of orf35 promoter.
AP-1 is a dimeric transcription factor that consists of
members of the cFOS and cJUN gene subfamilies which bind
consensus DNA sites in the promoter region of target genes
(Shaulian and Karin, 2002; Karamouzis et al., 2007). The
activity of AP-1 is regulated at multiple levels, including
transcription of the genes encoding AP-1 subunits, control of
the stability of their mRNAs, posttranslational modifications,
turnover of the AP-1 components, and specific interactions with
other transcription factors and cofactors.
Previous studies established the involvement of AP-1 in
KSHV reactivation (Wang et al., 2004; Cohen et al., 2006), and
two groups demonstrated the activation of AP-1 by virus entry
events (Xie et al., 2005; Sharma-Walia et al., 2005).
Furthermore, several KSHV-encoded proteins can potentially
manipulate the activities of AP-1 in KSHV-infected cells. For
example, endogenous unphosphorylated cJUN is induced upon
expression of RTA which in turn is capable of engaging in a
protein interaction with cJUN (Wang et al., 2004), while a dose-
dependent stimulation of RTA activity by cJUN was reported by
Gwack and colleagues (Gwack et al., 2001). Furthermore, acooperative enhancement of the total cJUN transcriptional
activation potential by RTA and ORF49 has been suggested
(Gonzalez et al., 2006). Accordingly, RTA increases total cJUN
protein and ORF49 induces phosphorylation and activation of
cJUN, resulting in a synergistic activation of several KSHV lytic
promoters containing AP-1 sites. Wang and colleagues
confirmed a synergistic activation of RTA, MTA, and RAP
promoters by cJUN plus cFOS with RTA (Wang et al., 2004).
However, unlike the orf35 promoter, these promoters are
strongly activated by cJUN plus cFOS even in the absence of
RTA, and a more than additive effect is evident when RTA is
expressed with cJUN plus cFOS and vice versa. Furthermore,
the dependence of RTA activity in the DNA binding of AP-1 has
not been investigated in this study. To the best of our
knowledge, our report is the first to describe a dependence of
RTA transcriptional activation in the DNA binding of AP-1.
The mechanism by which RTA activates orf35 promoter by
means of AP-1 remains to be determined. Recruitment of RTA
to orf35 promoter by AP-1 transcription cofactors is possible.
Mutual modulation of AP-1 and RTA transcriptional activities
might also take place. Thus, binding of AP-1 and RTA to
different sites in the orf35 promoter may cooperatively yield
high transcriptional activation. The binding of both factors may
either generate an active ternary transcriptional complex or
induce conformational changes that allow the recruitment and
binding of additional cellular transcription factors. It is also
possible that RTA modulates the expression and/or activity of
the AP-1 transcription factor, which in turn regulate the orf35
promoter. This possibility is supported by Wang et al. (2004)
study, showing that RTA increases cJUN expression and is
capable of forming protein interaction with cJUN.
During primary infection, KSHV entry events activate AP-1,
and early stimulation of the RTA promoter is accomplished
predominantly via this pathway (Xie et al., 2005; Pan et al., 2006).
Unlike most other herpesviruses, KSHV quickly adopts a latent
program of gene expression following de novo infection in vitro.
However, the transient expression of a limited set of lytic viral
genes takes place rapidly after infection, prior to the establishment
of latency (Krishnan et al., 2004). Many of the transiently
expressed KSHV lytic genes possess immune modulation and
antiapoptotic functions, suggesting a role in providing conditions
necessary for the coexistence of the virus with the host cell during
the initial time of infection and/or during the establishment of
latency. orf35 has been included among this set of transiently
expressed genes (Krishnan et al., 2004), and involvement of the
AP-1 complex in its promoter activation further supports its
primary role during the initial phases of infection. Further studies
will reveal whether and in what manner the orf35 gene product
provides functional support for the early phases of KSHV
infection and/or during the establishment of latency.
Materials and methods
Sequence analyses
Alignments of KSHV ORF35 protein sequences were
compiled using ClustalW (Pearson, 1990). Additional sequence
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site prediction algorithm (Xue et al., 2006). KSHV ORF35
promoter sequences were analyzed using the MatInspector
program (Cartharius et al., 2005).
Culture conditions
BCBL-1 (KSHV-positive cell line) (Renne et al., 1996), BC-1
(KSHVand EBV-positive cell line) (Cesarman et al., 1995), and
BCP-1 (Boshoff et al., 1998) cells were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal calf
serum (FCS), 2 mM L-glutamine, 50 IU/ml of penicillin, and
50 μg/ml of streptomycin. Human embryonic 293T kidney cells
were cultured in Dulbecco's modified Eagle's medium supple-
mented with 10% FCS and antibiotics. Mouse RBP-Jκ−/−
(OT11) fibroblast cell line was kindly provided by T. Honjo
(Kyoto University, Japan) (Oka et al., 1995), and were grown in
high glucose DMEM supplemented with 10% FCS. Cells were
maintained at 37 °C in humidified atmosphere with 5% CO2. To
induce lytic KSHVinfection, cells were seeded at 4×105 cells/ml
and 12-O-tetradecanoyl 13-acetate (TPA; Sigma) was added at
20 ng/ml. To inhibit virus DNA replication, phosphonoacetic
acid (PAA) (Sigma) was added at a concentration of 0.5 mM.
Construction and screening of BC-1 cell line cDNA library
A cDNA phage library of BC-1 cells induced with TPAwas
kindly provided by Prof. Patrick Moore and Prof. Yuan Chang
(Pittsburgh University, PA) (Sarid et al., 1999). Clones
identified with a KSHV orf35 PCR probe were plaque purified;
positive phages were converted into phagemids by employing
the ExAssist helper phage (Stratagene), and inserts were
sequenced.
Reverse transcription (RT)-PCR and Northern blot analysis
Total cellular RNA was extracted with the use of EZ-RNA
Total RNA Isolation kit (Biological Industries, Kibbutz Beit
Haemek, Israel), according to the manufacturer's instructions.
DNase I (Ambion)-digested RNA (1 μg) was reverse tran-
scribed with random hexamers and RevertAid H Minus First
Strand cDNA synthesis kit (Fermentas) according to the
manufacturer's protocol. −RT reactions were used to control
for DNA contamination. For PCR amplification, 10% of the
reverse transcribed RNA was added to a reaction buffer
containing a mixture of dNTPs (200 μM each), 1 μM of
oligonucleotide primers for orf35, orf65, or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and 2 U Taq polymerase.
Following 2 min denaturation at 94 °C, 35 amplification cycles
were performed as follows: 94 °C for 30 sec, 58 °C for 1 min,
72 °C for 1 min, and 72 °C for 10 min. Samples were collected
after 15, 20, 25, 30, and 35 amplification cycles and products
were analyzed by gel electrophoresis using a 1.5% agarose gel
stained with ethidium bromide.
For Northern blot hybridization, RNA was fractionated by
electrophoresis on 1% agarose-1.6% formaldehyde in MOPS-
EDTA buffer, and then transferred to nylon membrane(Schliecher and Schuell, Germany) over night in 10× SSC.
PCR products from orf35 and GAPDH were 32P-labeled by
random priming (Biological Industries, Kibbutz Beit Haemek,
Israel) and hybridized to the blots at 42 °C in [5× SSC, 50%
formamide, 5× Denhardt's solution, 2% sodium dodecyl sulfate
(SDS), 10% dextran sulfate, 100 μg denatured sheared salmon
sperm DNA/ml]. Multiple post hybridization washes were
carried out in 1× SSC, 0.1% SDS at 68 °C.
Primer extension
Total cellular RNAwas prepared with EZ-RNA according to
the manufacturer's protocol (Biological Industries, Kibbutz Beit
Haemek, Israel). Primer PE 5′-GGCCTCCAGAGCCGACT-
TAATAAAC-3′ was end-labeled with [γ-32P]ATP (105 cpm/
pmol) and hybridized to 10 μg of RNA at 60 °C for 15 min. The
sample was then kept on ice for 1 min. Next, 1 unit of reverse
transcriptase (Expand RT, Roche) and 1 unit of RNase inhibitor
(Promega) were added, and extension was performed at 42 °C
for 90 min. Reaction products were precipitated with ethanol
and resolved on a 6% polyacrylamide, 7 M urea gel in Tris–
borate–EDTA. DNA sequencing reactions were performed with
Sequenase 2.0 (United States Biochemical Corporation, Cleve-
land, Ohio).
Plasmids
The viral DNA from KSHV-infected BCBL-1 cells was used
as a template for all PCR amplifications. The KSHV orf35 gene
fragment was amplified by PCR primers with BamHI and EcoRI
restriction sites at their 5′ and 3′ ends (5′-TTGGGATCCATG-
GACTCAACCAACTCT-3′ and 5′-TGGGAATTCTTAGG-
GAGTTTCAGGGCA-3′), respectively, and inserted into
pcDNA/HA (Invitrogen) to obtain pcDNA/HA-ORF35, which
allows gene expression in mammalian cells in-frame with an
N-terminal HA tag. PCR products that were generated with
primers containing XhoI and EcoRI restriction sites at their 5′
and 3′ ends (5′-TTGCTCGAGGAATGGACTCAACCAACT-
3′ and 5′-TGGGAATTCTTAGGGAGTTTCAGGGCA-3′)
were cloned into pEGFP-C1 (BD Biosciences) to obtain
pEGFP-ORF35. The RTA expression plasmid (pcDNA-
ORF50) (Lukac et al., 1998) and PAN1 promoter reporter
construct (Kirshner et al., 2000) were kindly provided by Prof.
Don Ganem (University of California, San Francisco, CA).
HumanHA-cFOS and cJUN expression pcDNA3 plasmids were
kindly provided by Prof. Yosef Shaul (Weizmann Institute of
Science, Israel). Flag-tagged cFOS dominant-negative (A-FOS)
expression vector was obtained from Prof. Charles Vinson
(National Institutes of Health, Bethesda, Maryland) (Olive et al.,
1997). Human full-length RBP-Jκ expression plasmid was
kindly provided by Prof. Delphine Ndiaye (Pasteur Institute,
Paris).
To generate deletion mutant promoter constructs, the KSHV
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GGGACGCGTGTCGTTCGTTAATCATGCCCT-3′, and 5′-
AAAACGCGTCGGAACTTGGAAGGGTCTTC-3′ to obtain
fragments that are 176, 216, 262, 362, and 533 nt from the orf35
ATG codon. PCR products were cloned into pGL3-basic (Pro-
mega) with XhoI and MluI cloning sites. The mutated reporter
clone −262ORF35mp, with TGAG at positions −249 to −246
replaced with GATC to destroy the AP-1-binding site, was
generated by using the −262 deletion mutant promoter plasmid
as a template, a mutated AP-1 sense primer 5′-GGGACGCG-
TATACAAAGGGTAGGATCTCAGATGAAA-3′ and the anti-
sense primer described above.
Western blot analysis
Cells were washed twice in cold phosphate-buffered saline
(PBS), suspended in lysis buffer (50 mM Tris–HCl, pH 8.0,
150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonident P-40,
0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 50 μg/ml
aprotinin, 50 μM leupeptin, 0.2 mM Na3VO4, 50 mM NaF) and
incubated on ice for 30 min. Then cell debris was removed by
centrifugation at 12,000×g for 15 min at 4 °C. Loading buffer
(2×; 2% SDS, 20% glycerol, 125 mM Tris (pH 6.8), 0.02%
bromophenol blue, and 10% β-mercaptoethanol) was added and
the samples were boiled for 5 min. Protein lysates were resolved
by SDS-polyacrylamide gel (PAGE) and transferred to
nitrocellulose membranes (Schliecher and Schuell). The protein
contents of different samples were verified to be similar by
Ponceau staining. The nitrocellulose membranes were blocked
with 5% dry milk in TBS and subsequently incubated with
primary antibody (mouse anti-HA (HA.11) (Covance Research
Products), anti-GFP (Covance Research Products), rabbit anti-
ORF35, anti-RTA (kindly obtained from Dr. Keiji Ueda, Osaka
University School of Medicine, Osaka, Japan), anti-Tubulin
(Sigma), or anti-Flag (Sigma). Specific reactive bands were
detected using goat anti-rabbit IgG or goat anti-mouse
conjugated to horseradish peroxidase. Immunoreactive bands
were visualized using the enhanced chemiluminescence (ECL)
Western blotting detection kit (Amersham, Arlington Heights,
IL).
In vitro transcription/translation
In vitro transcription and translation were carried out using a
T7/T3 in vitro transcription and translation kit according to the
manufacturer's protocol (Promega). Radiolabeled in vitro-
synthesized proteins were obtained by adding [35S]methionine.
Proteins from each sample were assayed by Western blot and
used for EMSA or electrophoresed in SDS-PAGE, dried, and
exposed to film.
DNA transfection and reporter assays
DNA transfections into HEK-293T cells were carried out
with the calcium phosphate method. DNA transfections into
OT11 cells were performed using Lipofectamine 2000 transfec-
tion reagent (Invitrogen) according to the manufacturer'sprotocol. Cell lysates were prepared 48 h after transfection and
luciferase activity was measured using the Promega luciferase
kit in a Spectralfluor Plus luminometer (Tecan) according to the
manufacturer's instructions. To control for transfection effi-
ciency, we performed cotransfection with plasmid pcDNA-LacZ
expressing β-galactosidase. In all cases, three or more separate
transfections were performed, and results shown are representa-
tive of at least three experiments.
Electrophoretic mobility shift assay (EMSA)
RTA, cJUN, and cFOS protein samples used for EMSAwere
in vitro translated with the T7-TNT quick-coupled transcrip-
tion-translation system (Promega) according to the manufac-
turer's procedures, and using the corresponding expression
plasmids pcDNA-RTA, pcDNA3-HA-hcFOS, and pcDNA3-
hcJUN as templates. Next, 10 pmol of annealed double-
stranded oligonucleotides was end radiolabled with [γ-32P]ATP
using T4 polynucleotide kinase (PNK). For gel shift assays, 4 μl
of in vitro-translated proteins was incubated for 10 min at R.T.
in a binding buffer containing 50 mM Tris–HCl (pH 7.5),
250 mM NaCl, 5 mM MgCl2, 20% glycerol, 2.5 mM EDTA,
2.5 mM dithiothreitol, and 0.25 μg/μl of poly(dI/dC). The 32P-
labled probe was then added and incubated for 20 min at R.T.
Competition assays were carried out in the same manner, except
that the above reaction mixture was preincubated with excess
cold probe before the addition of the labeled probe. For
supershift experiments, 3 μg of mouse anti-HA monoclonal
antibody (MMS-101R, Covence) was added to the mixture and
allowed to incubate for another 30 min before gel loading.
Samples were separated by 5% nondenaturing PAGE. The gels
were dried and subjected to autoradiography.
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